TRPC5 and breast carcinoma: Additionally, we found that long-time treatment (4 weeks) of MCF-7, SK-BR-3, and MCF-7/ADM cells with Gd-DTPA and gadodiamide upregulated TRPC5 expression and decreased the accumulation of ADM in breast cancer cell nuclei, which was abolished by TRPC5 antagonist, AC1903.